CIHR funding rate: 13.6%.
Early 2000s: 30%+.
Canadaβs new $1.7B Impact+ program recruits talent β but without increased Tri-Council base funding, we risk further strain on an already stretched system.
Weβre calling for $1B over 5 years.
Support here: tinyurl.com/33c5av46
13.02.2026 18:55 β π 44 π 29 π¬ 3 π 1
What is your University internal deadline like? Single deadline or double deadline?
-CIHR LOI date Feb 4, 2026
-Dalhousie FoM internal deadline on Uni server Feb 12, 2026
-Dalhousie ORS internal deadline on Uni server & ResearchNet Feb 17, 2026
CIHR Deadline Mar 4, 2016 @dalhousieu.bsky.social
12.02.2026 21:17 β π 6 π 4 π¬ 1 π 0
Proanthocyanidins enhance antitumor immunity by promoting ubiquitin-proteasomal PD-L1 degradation via stabilization of LKB1 and SYVN1 @jci.org
www.jci.org/articles/vie...
03.02.2026 21:59 β π 1 π 1 π¬ 0 π 0
This preprint maps synthetic lethal (SL) targets across 15 common cancer drivers using genome-wide CRISPR KO screens in isogenic cell line pairs plus a large-scale comparison to DepMap.
www.biorxiv.org/content/10.6...
04.02.2026 20:30 β π 1 π 0 π¬ 0 π 0
What if βundruggableβ cancer drivers are druggable indirectly?
New bioRxiv preprint: 15 CRISPR synthetic lethality screens + DepMap, then validation with clonogenic assays counted on GelCount.
ARID1AβGFPT1, STK11βMARK2, FBXW7βPKMYT1.
Read here: www.biorxiv.org/content/10.6...
04.02.2026 01:07 β π 1 π 1 π¬ 0 π 0
CRISPR screens in iPSC-derived neurons reveal principles of tau proteostasis
CRISPR screens in iPSC-derived neurons reveal that the E3 ubiquitin ligase CRL5SOCS4
ubiquitinates tau, that CUL5 expression is correlated with resilience in human Alzheimerβs
disease, and that electr...
After a long review process, I'm excited that our paper is finally in print: www.cell.com/cell/fulltex...
TL;DR: We use CRISPR screens in iPSC-derived neurons to find a new tau E3 ligase and a relationship between oxidative stress, the proteasome, and tau proteolytic fragments.
More below π
28.01.2026 17:12 β π 35 π 11 π¬ 2 π 1
A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance | PNAS
Pancreatic ductal adenocarcinoma (PDAC) has one of the lowest cancer survival rates.
Recent studies using RAS inhibitors have opened the door to mo...
As generalized before, most cancer promoting genes are enriched in embryonic neural/neural stemness cells, incl. KRAS/HER2/EGFR/STAT3.
They confer cancer cell with neural stemness, which determines tumorigenicity&pluripotency in cells. @pnas.org
www.pnas.org/doi/10.1073/...
29.01.2026 06:37 β π 3 π 1 π¬ 0 π 2
STK11 mutations and deletions define a distinct subtype of cervical adenocarcinoma https://www.medrxiv.org/content/10.64898/2026.01.01.25343162v1
05.01.2026 01:25 β π 2 π 1 π¬ 0 π 0
π "LKB1 acts as a nexus between metabolism and gene expression, acting via the SMARCA4-SWI/SNF complex to regulate gene expression in lung cancer."
New preprint out of Marignani Lab
@pmarignani.bsky.social
29.01.2026 00:48 β π 4 π 1 π¬ 0 π 0
Tumour suppressors LKB1 and SMARCA4 functionally interact to regulate gene expression of diverse biological processes in lung cancer https://www.biorxiv.org/content/10.64898/2026.01.26.699134v1
28.01.2026 22:47 β π 2 π 1 π¬ 0 π 1
This review examines the roles of #LKB1/STK11 in #cancer, detailing its #TumorSuppressive functions, regulation via #AMPK signaling and #AdaptorProteins, and discusses the challenges of developing LKB1-targeted inhibitors. @westernu.bsky.social
#OpenAccess: doi.org/10.1016/j.ge...
24.12.2025 16:34 β π 1 π 1 π¬ 0 π 0
Critical role for a high-plasticity cell state in lung cancer @nature.com @mskcancercenter.bsky.social
www.nature.com/articles/s41...
21.01.2026 17:57 β π 5 π 2 π¬ 0 π 0
02.01.2026 01:09 β π 28 π 3 π¬ 1 π 0
Single-cell RNA-seq is younger than the iPhone. π€― The first bona fide scRNA-seq transcriptomes were published in 2009 by Tang et al., who sequenced individual mouse cells and showed you could capture a whole transcriptome from a single cell. From βsci-fiβ to standard tool in just over a decade...
25.11.2025 01:47 β π 6 π 1 π¬ 1 π 0
From "The Tumor Suppressor Kinase LKB1: Metabolic Nexus" by Mohammed Bourouh, Paola A. Marignani.
HIF1Ξ± promotes expression of glycolytic enzymes. Schematic representation of glycolysis and the pentose phosphate pathway (PPP). LKB1 phosphorylates and activates AMPK which then phosphorylates and inhibits RAPTOR, thereby inhibiting mTORC1. mTORC1 promotes HIF1Ξ± upregulation. Active HIF1Ξ± promotes expression of glycolytic enzymes (red) increasing glycolysis rate. HIF1Ξ± also promotes expression of 6PGD to shunt glucose-6-phosphate to the PPP to generate NADPH for REDOX balance and for synthesis of ribose-5-phosphate for nucleotide synthesis.
www.frontiersin.org/journals/cel...
Review: "The Tumor Suppressor Kinase LKB1: Metabolic Nexus"
LKB1 loss is associated with multiple malignancies and causes metabolic reprograming to increase glycolysis and lactate production, elevate hexosamine biosynthesis and glutamine metabolism.
25.11.2025 01:26 β π 3 π 2 π¬ 0 π 0
π¬New Preprint Alert π¬ How is AMPK regulated by oxidative stress? We use functional imaging to uncover spatial regulation of AMPK activity during oxidative stress by LKB1 & CaMKK2. Combining imaging with proteomics & metabolomics, we find AMPK works to promote the cellular redox response.
18.11.2025 03:56 β π 15 π 8 π¬ 1 π 0
www.sciencedirect.com/science/arti...
Authors combined targeted NGS with STAS and LVI scoring and organ-specific metastasis profiling within a single well-defined NSCLC cohort. This design allows them to directly link #STK11 mutation subtypes with distinct clinical and metastatic phenotypes. #LKB1
24.11.2025 03:05 β π 1 π 0 π¬ 1 π 0
The authors also show in vivo protection against IgE-mediated anaphylaxis, hinting that AMPK agonists could be a real therapeutic avenue.
24.11.2025 02:58 β π 2 π 0 π¬ 0 π 0
Whatβs striking is how zingerone works. By boosting LKB1/AMPK signaling, it reins in mast cell activation at the source, lowering CaΒ²βΊ influx, reducing granule release, and dampening the whole allergic cascade. Itβs a metabolic lever with immunological consequences.
24.11.2025 02:57 β π 3 π 0 π¬ 1 π 0
www.mdpi.com/1467-3045/47...
Zingerone, a ginger-derived compound, activates the LKB1/AMPK pathway to block IgE/FcΞ΅RI-dependent mast cell degranulation and anaphylaxis in models. Highlights AMPK agonists as potential anti-allergic therapeutics.
24.11.2025 02:56 β π 2 π 0 π¬ 1 π 0
This review highlights the role of #LKB1 in #Tumorigenesis and its therapeutic relevance in #Oncology, offering new insights into targeted #CancerTherapy. @westernu.bsky.social #medsky
#OpenAccess: www.sciencedirect.com/science/arti...
08.11.2025 15:53 β π 1 π 1 π¬ 0 π 0
Postdoctoral researcher in the Lewandowski, Stansfeld and Dowson labs @ Warwick | Former postdoctoral researcher in the Marrink lab @ Groningen University | Views are my own | She/her π³οΈβπ
https://orcid.org/0000-0003-2006-5015
Infectious disease epidemiologist.
Klebsiella pneumoniae & neonatal sepsis, AMR, vaccine coverage, Bayesian methods & transmission modelling.
Found in North Lanarkshire π΄σ §σ ’σ ³σ £σ ΄σ Ώ
Autistic & π³οΈβπ (he/him)
www.keegan.science
A community-building and networking initiative aimed at improving justice and belonging for 2SLGBTQIA+ microbiologists in academia and beyond!
Website: https://prideinmicro.org/
Thoracic Surgeon, Sheffield, UK
CWIS, BTOG, ESTS, IASLC
Medical Oncologist #SCLC at Vall dβHebron University Hospital, Barcelona, Spain | IASLC SCLC Committee member | Former MDAnderson Cancer Center Postdoctoral Fellow
Lung cancer patient and research advocate. Cofounder #LCSM Chat, The ROS1ders, IASLC STARS. Also writer, retired engineer, science geek. Temporarily between feline overseers. Blog at grayconnections.net.
Medical Oncologist, Director 4th Oncology Dept & Clinical Trials Center Metropolitan Hospital, Athens, PhD Imperial College London, ESMO W4O Chair, ESMO Council member, IASLC Academy mentor & Education Committee member
#MedSky #OncSky #LCSM #equity
Director of Thoracic Oncology and Head of Developmental Therapeutics at Georgetown University Lombardi Comprehensive Cancer Center, co-Host of the IASLC Podcast
#LCSM #MedSky #OncSky #HereWeGo #Steelers #LetsGoBucs
Postdoc in the Rawlins lab @ The Gurdon institute; studying cell lineages in the developing human lung. Not super serious about other things like food and beer and cycling.
Professor of Respiratory Science University of Cambridge. Lung doctor. Fellow St Catharineβs College. Cell biology. Pleural medicine. Rare disease. Genetics.
Lab webpage = https://www.cimr.cam.ac.uk/staff/professor-stefan-marciniak
Scientist, physician, husband, father of daughters.
I study how cell metabolism contributes to the lung diseases pulmonary hypertension and fibrosis.
oldhamlab.org
Scientist by day, defender of lost causes by night. Especially the right to not spend our lives filling online forms.
Cell death, Cancer metabolism, Metabolic stress, ISR/UPR, mesothelioma and lung cancer
Diagnosed with stage 4 small cell lung cancer. Still alive and kicking for now but I know it's only a matter of time. Living with my absolutely wonderful, thoughtful, tough wife, 2 dogs and 2 elderly cats.
Lung and ICU doctor in Cincinnati. Lung progenitor cell and regeneration researcher. Physician scientist/Academic husband/dad. http://zachariaslunglab.com.
Postdoc@Stanford | PhD@Cambridge | Research interests: human development, stem cells, organoids, lung disease, hypoxia, single-cell genomics, cell signalling
Postdoc in Joseph Powell's lab at the Garvan Institute of Medical Research using Genomics to understand Interstitial Lung Disease π«
Views are my own
Studying genomics, transcriptomics, and all things data science in interstitial lung disease at Columbia University.
#StemCells Researcher | Director of the Cell Processing Facility
University of Montpellier - CHU of Montpellier | #StemCells #iPScells for #lung #CellTherapy |
Stem Genomics co-founder | President of the FSSCR
Research Scientist | National Cancer Centre Singapore π©π»ββοΈ| Lung cancer genomics π« | Alumni postdoc π§¬π¬@sangerinstitute
I'm a researcher with wide interests, including clinical genomics (duplications in acrocentric chromosomes), rare cancers (unusual histotypes of lung cancer and childhood malignancies), rare diseases, and autism driven by chromosomal duplications.